A Part of the University of Maryland Medical Center

Connect with UMGCC
Facebook Twitter YouTube Blog iPhone
Email PageEmail page Print PagePrint page

Hematologic Malignancies



Ask the Expert

Dr. Baer’s Bio Image

Get answers to your Myelodysplastic Syndromes questions.

Dr. Baer’s Bio | Q&A Archive

Note: This is for informational purposes only. Doctors cannot provide a diagnosis or individual treatment advice via e-mail. Please consult your physician about your specific health care concerns.

Related Content


Hematologic Malignancies treatment at the University of Maryland Marlene and Stewart Greenebaum Cancer Center (UMGCC) is built on a long-standing tradition of excellence. From its inception as an extramural program of the National Cancer Institute, UMGCC has been at the forefront of developing and testing new therapies for hematologic malignancies.

With one of the largest experimental therapeutics programs on the East Coast, we offer experimental therapies for all stages of leukemia, lymphoma, Hodgkin's disease and multiple myeloma. Our center is a member of the Myeloproliferative Disorders Research Consortium, an NIH-funded international clinical trials group focusing on myeloproliferative disorders.

Our team of experts includes internationally and nationally recognized leaders in this field, and we continue to set the standard for treating patients with:

Working with referring physicians to provide patients with the best possible care, we treat all types of hematologic malignancies. Our experts work together throughout the treatment process to ensure that patients receive the highly individualized program of care they need while undergoing complex, aggressive therapies.

What's Inside Department News
This page was last updated on: December 27, 2013.

For More Information